|
06 Apr 2021 |
Molecular Templates to Prioritize Next-Generation ETB Candidates
|
|
06 Apr 2021 |
AEON Biopharma Doses First Patient in Phase 2 Trial of ABP-450 for the Treatment of Cervical Dystonia
|
|
06 Apr 2021 |
Sorrento Enters Into Merger Agreement to Acquire Late-Stage Oncology Company ACEA Therapeutics
|
|
06 Apr 2021 |
Turning Point Therapeutics Announces Initial Clinical Data From Phase 1/2 SWORD-1 Study of RET Inhibitor TPX-0046
|
|
06 Apr 2021 |
Molecular Partners Announces First Patient Dosed in a Phase 2 Clinical Trial of Ensovibep in COVID-19 Patients
|
|
06 Apr 2021 |
Valneva Reports Positive Phase 1/2 Data for Its Inactivated, Adjuvanted COVID-19 Vaccine Candidate, VLA2001
|
|
06 Apr 2021 |
Novavax Initiates COVID-19 Vaccine Clinical Trial Crossover
|
|
06 Apr 2021 |
Exelixis Announces U.S. FDA Accepts Investigational New Drug Application for XB002 in Patients with Advanced Solid Tumors
|
|
06 Apr 2021 |
Teneobio Announces Achievement of Milestone Payment as Janssen Advances Phase I Study of Bispecific JNJ-75348780 for the Treatment of NHL and CLL
|
|
05 Apr 2021 |
Cidara Therapeutics Announces Agreement with Janssen to Develop and Commercialize AVCs for the Prevention and Treatment of Influenza
|
|
05 Apr 2021 |
Ionis initiates Phase 3 trial of novel antisense medicine to treat leading cause of juvenile-onset ALS
|
|
02 Apr 2021 |
Celon Pharma Announces CPL’280, Second Generation Oral GPR40 Agonist, Meets Primary Endpoint in Phase 1 Trial
|
|
02 Apr 2021 |
Passage Bio Announces First Patient Dosed in Imagine-1 Study of PBGM01 Gene Therapy for Infantile GM1 Gangliosidosis
|
|
02 Apr 2021 |
Arbutus Biopharma, X-Chem and Proteros biostructures Enter into a Pan-Coronavirus Discovery Research and License Agreement
|
|
02 Apr 2021 |
OSE Immunotherapeutics Receives Authorization for Phase 1 Clinical Trial of its Multi-Target Multi-Variant COVID-19 Vaccine
|
|
02 Apr 2021 |
US FDA Approved Jemincare to Initiate Clinical Trial of Neutralizing Antibody JMB2002
|
|
02 Apr 2021 |
AbCellera and Gilead Sciences Announce New Multi-Year, Multi-Target Antibody Discovery Collaboration
|
|
02 Apr 2021 |
CoVIg-19 Plasma Alliance Announces Topline Results from NIH-Sponsored Clinical Trial of Investigational COVID-19 Hyperimmune Globulin Medicine
|
|
02 Apr 2021 |
Kite Submits Supplemental Biologics License Application to U.S. Food and Drug Administration for Tecartus in Adult Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
|
|
02 Apr 2021 |
Eloxx Pharmaceuticals Acquires Zikani Therapeutics
|
